MESO Mesoblast Limited

+0.01  (+0%)
Previous Close 5.1
Open 5.22
Price To Book 0.97
Market Cap 508360194
Shares 99,483,404
Volume 13,916
Short Ratio
Av. Daily Volume 61,228

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b Class IV primary endpoint reached 1Q 2018.
MPC-150-IM - Class IV
Chronic heart failure (CHF)
Phase 3 completion of enrollment announced March 29, 2018.
Chronic low back pain
BLA filing due following FDA meeting in April 2019.
acute graft versus host disease (aGVHD) in children
Phase 2 data released August 2016. Partnership required for Phase 3 development.
Rheumatoid arthritis
Phase 3 enrolment to be completed 1Q 2019.
MPC-150-IM - Class 2/3
Heart failure
Phase 2b trial did not meet primary endpoint - November 11, 2018.
End-Stage Heart Failure with LVADs

Latest News

  1. Mesoblast to Present at 2019 RBC Capital Markets Global Healthcare Conference
  2. What Kind Of Shareholders Own Mesoblast Limited (ASX:MSB)?
  3. FDA Agrees to Rolling Review of Mesoblast’s Biologics License Application for Its Cell Therapy in Children With Steroid-Refractory Acute Graft Versus Host Disease
  4. Should You Be Pleased About The CEO Pay At Mesoblast Limited's (ASX:MSB)
  5. Mesoblast to Present at Upcoming Global Life Sciences Conference in London
  6. Memorandum of Understanding for Confirmatory Trial to Support Marketing Approval of Revascor for Reduction of Gastrointestinal Bleeding in LVAD Patients
  7. Mesoblast Licensee Files for Marketing Approval to Treat Epidermolysis Bullosa
  8. U.S. Healthcare Leader Joseph R. Swedish Appointed Mesoblast Chairman
  9. Mesoblast Features at Upcoming U.S. Investor Conferences
  10. Mesoblast Reports Financial Results and Operational Highlights for the First Half Ended December 31, 2018
  11. Final Patient Dosed in Mesoblast Phase 3 Trial of Revascor Cell Therapy for Advanced Heart Failure
  12. Mesoblast Financial Results Webcast for Half Year, Q2 Ended December 31, 2018
  13. New Research Coverage Highlights Symantec, YY, Workiva, Exponent, Ferroglobe, and Mesoblast — Consolidated Revenues, Company Growth, and Expectations for 2019
  14. Hercules Capital Provides US$15M From Existing Facility for Mesoblast to Accelerate Product Commercialization Programs
  15. Does The Mesoblast Limited (ASX:MSB) Share Price Tend To Follow The Market?
  16. Mesoblast Highlights 2019 Key Priorities for its Leading Cellular Medicines Pipeline at Biotech Showcase in San Francisco
  17. Phase 3 Trial of Mesoblast’s Cell Therapy in Chronic Heart Failure Completes Recruitment
  18. Mesoblast Corporate Review
  19. Mesoblast to Present at 2019 Biotech Showcase in San Francisco
  20. Mesoblast Makes Executive Appointment to Drive Product Commercialization